Breaking Canadian GLP-1 news
GLP-1 News — Page 3
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Pharmacy-Level Generic Semaglutide Switch Mechanics Detailed
Endor Health details how Canadian pharmacies will substitute generic semaglutide at refill, with pCPA tiers setting public-plan prices at 85% down to 35% of brand.
Sandoz Cites Brazil Priority Review as Canada Wait Stretches On
Sandoz Canada points to Brazil's proactive prioritization of generic semaglutide submissions as the Canadian regulator continues to send back questions a year after filing.
Health Canada Review Cites 7.1M GLP-1 Prescriptions in 2023
Health Canada's Summary Safety Review discloses 7.1 million GLP-1 receptor agonist prescriptions dispensed by Canadian retail pharmacies in 2023.
Federal Budget Skips Health Canada Generic Backlog Fix: CGPA
Canada's federal budget omitted new Health Canada resources to clear a generic drug backlog, drawing criticism from CGPA's Jim Keon as semaglutide files queue.
Alberta Blue Cross: GLP-1 Plan Spend Won't Fall Despite Generic
Alberta Blue Cross's 2026 pipeline report says GLP-1 plan spend is unlikely to fall despite a mid-2026 semaglutide generic, citing expanding uses and growing demand.
Novo Nordisk Details SOUL Trial Behind Rybelsus MACE Approval
Novo Nordisk Canada president Vince Lamanna detailed the SOUL trial of 9,650 patients behind Health Canada's MACE indication expansion for Rybelsus tablets.
Seven Generic Semaglutide Files Remain Under Health Canada Review
Health Canada is reviewing seven additional generic semaglutide submissions after Dr. Reddy's and Apotex authorizations, with more decisions expected in coming weeks.
Novo Nordisk Aligns Brand Ozempic Price With Generics in Canada
Novo Nordisk cuts brand-name Ozempic pricing for uninsured Canadians via its Savings Card, aligning costs with newly arrived generics from Apotex and Dr. Reddy's.
Eli Lilly Raises Mounjaro Prices in Canada Amid Trump Pressure
Eli Lilly raised Mounjaro list prices in Canada and Britain after Trump administration pressure, with Kwikpen wholesale prices now ranging $387 to $773.
Health Canada Safety Review: No GLP-1 Suicide Link in T2D Patients
Health Canada's Summary Safety Review found no evidence linking GLP-1 receptor agonists to suicide or self-harm in type 2 diabetes patients; obesity data inconclusive.
Apotex, Dr Reddy's Map Divergent Global Paths for Generic Semaglutide
Apotex CEO Martin Arès says the company is exploring US access routes while Dr Reddy's targets 80+ countries excluding US, UK and Europe.
TrumpRx Starts at US$350, Phases to US$245 as Canada Goes Generic
TrumpRx will sell GLP-1s starting at US$350, dropping to US$245 over two years, while Canada has approved two generic semaglutides, CBC and BMJ report.
Dr. Reddy's Generic Semaglutide Cleared NOD, NON Before Approval
Health Canada's Regulatory Decision Summary reveals Dr. Reddy's generic semaglutide cleared a Notice of Deficiency and Notice of Non-Compliance before April 28 approval.
Novo Nordisk Rebrands: Plosbrio, Poviztra Approved Dec 22, 2025
Health Canada approved two Novo Nordisk rebranded semaglutide products, Plosbrio and Poviztra, on December 22, 2025, as a defensive move against generics.
BBC Profiles Ottawa Patient Paying C$350-C$500 Monthly for Wegovy
BBC profiles Ottawa retiree Elizabeth Doran, 69, who paid C$350-C$500 monthly out of pocket for Wegovy and took substitute teaching shifts to afford it.
BBC: US Patients Eye Canadian Generic Semaglutide as Prices Diverge
BBC reports Americans may look north for generic semaglutide as Canadian patients access generics priced at less than a third of brand cost.
Selectpath Urges Plan Sponsors to Mandate Generic Substitution
Selectpath advisor warns Canadian plan sponsors that lower generic semaglutide prices may not cut total spend without mandatory substitution and tighter prior authorization.
Dr. Reddy's CEO Israeli Frames Canada Launch as Access Mission
Dr. Reddy's CEO Erez Israeli says the company remains dedicated to expanding GLP-1 access in Canada after becoming first to win generic semaglutide approval.
Alberta Blue Cross 2026 Pipeline: GLP-1 'Second Wave' Coming
Alberta Blue Cross's 2026 drug pipeline report flags a second wave of GLP-1 innovation, with MASH and sleep apnea indications keeping plan spend high.
Novo Nordisk: More Than 1 Million Canadians Take Semaglutide
Novo Nordisk says more than a million Canadians take a semaglutide drug, as CGPA reports 500+ generic submissions under Health Canada review with 100+ backlogged.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada